Cancer imaging using 18 F-FMISO has been developed over the past 30 years and is the most established agent for noninvasively assessing hypoxia. Research into hypoxia imaging agents began, as many imaging agents arise, through laboratory investigations using cultured cancer cells in controlled oxygen environments (1) . Development of 18 F-FMISO was validated through studies of cell spheroids, animal imaging and tissue validation (2-4), and eventually human imaging in cancer patients (5) . The process of development of a PET imaging agent for hypoxia in human imaging necessarily proceeded from a complex dynamic imaging protocol with concomitant arterial sampling to a simple clinically feasible static imaging session without blood sampling, maintaining quantitative accuracy required to make the imaging study clinically useful.
Current static imaging methods for 18 F-FMISO quantification of hypoxia distribution have been shown to be useful in prediction of outcome and time to progression in a wide range of cancers (6) (7) (8) (9) . We have proposed using FMISO hypoxic volume (HV) distribution, where HV are the pixels greater than a tissue-to-blood ratio of 1.2, for planning hypoxia-targeted regions for escalated RT dose (10) . This approach has been tested in patients with head and neck cancer and found to be not only feasible, but superior to uniform dose prescription (11) (12) (13) .
In this issue a proposal is provided using a dynamic imaging sequence with kinetic analysis of 18 F-FMISO, potentially to generate an equivalent image of hypoxia for dose planning (14) . A similar distribution from dynamic 18 F-FMISO imaging would require a much longer dynamic imaging session and possibly blood sampling for input function determination, in addition to specialized software for the creation of parametric images from the dynamic sequence. Dynamic imaging protocols aren't considered clinically feasible for routine imaging performed at most medical centers unless they have been demonstrated to provide substantial added benefit over simple static images, in a positive cost/benefit ratio. To summarize, 18 F-FMISO PET started with 2 hr dynamic protocols with kinetic analysis but clinical studies have affirmed that static images at a time after injection when this freely diffusible radiopharmaceutical has distributed uniformly to normoxic tissue is useful. At this time after tracer injection only hypoxic tissues show increased uptake well above the equilibrium ratio of one. The nuclear medicine community is best served by keeping protocols as simple as possible and it is the requirement of investigators
